術前化学放射線療法
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Conroy T, Castan F, Etienne PL, et al. Ann Oncol. 2024 O…
Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-16): an open-label, multicentre, single-arm, phase 2 trial.Gani C, Fokas E, Polat B, et al. Lancet Gastroenterol Hepatol. 2025 Jun;10(6):562…
Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR).Jin J, Tang Y, Hu C, et al. J Clin Oncol. 2022 May 20;40(15):1681-1692. do…
Post-hoc analysis of clinicopathological factors affecting lateral lymph node metastasis based on STELLAR study for rectal cancer. Chen LN, Jiang J, Jiang LM, et al. Radiother Oncol. 2024 Nov;200:110512. doi: 10.1016/j.radonc.2024.110512. …
Preoperative Chemoradiotherapy for Resectable Gastric Cancer.Leong T, Smithers BM, Michael M, et al. N Engl J Med. 2024 Nov 14;391(19):1810-1821. doi: 10.1056/NEJMoa2405195. Epub 2024 Sep 14. PMID: 39282905. 【概要】・胃がん/食道接合部がん…
Higher Neoadjuvant Radiation Dose is Associated with Lower Overall Survival in Resected Esophageal Cancer: A Propensity-Matched National Cancer Database Analysis. Sutton TL, Patel RK, Elsheikh M, et al. Ann Surg Oncol. 2025 Sep 16. doi: 10…
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial. Janssen QP, van Dam JL, van Bekkum M…
Role of Lateral Pelvic Lymph Node Dissection Following Neoadjuvant Chemoradiation Therapy in Rectal Cancer: A Multicenter Retrospective Study (KROG 22-09).Yang E, Yoo GS, Park HC, et al. Ann Surg Oncol. 2025 Sep 5. doi: 10.1245/s10434-025-…
Dual Immune Checkpoint Inhibition Plus Neoadjuvant Chemoradiotherapy in Rectal Cancer: A Randomized Clinical Trial. Laengle J, Kuehrer I, Kulu A, et al. JAMA Netw Open. 2025 Aug 1;8(8):e2527769. doi: 10.1001/jamanetworkopen.2025.27769. PMI…
Preoperative chemoradiotherapy for esophageal or junctional cancer.van Hagen P, Hulshof MC, van Lanschot JJ, et al. N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088. PMID: 22646630. 【概要】・食道がん/食道胃接合部がん…
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial.Eyck BM, van Lanschot JJB, Hulshof MCCM, et al. J Clin Oncol. 2021 Jun 20;39(18):1995-2004. doi: 10.1200/JCO.20.036…
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. Kelly RJ, Ajani JA, Kuzdzal J, et al. N Engl J Med. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125. Erratum in: N Engl J Med. 2023 Feb 16;388(7):672. …
Phase I/II Trial of Perioperative Avelumab in Combination With Chemoradiation in the Treatment of Stage II/III Resectable Esophageal and Gastroesophageal Junction Cancer.Uboha NV, Basree MM, Eickhoff JC, et al. J Surg Oncol. 2025 Jun;131(7…
Neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a clinical retrospective study.Chen J, Miao C, Wang X, et al. BMC Cancer. 2025 Aug 5;25(…
Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Y…
Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial. Deng Y, Chi P, Lan P, et al. J Clin Oncol. 2019 Dec 1;37(34):3223-3233…
A new treatment strategy for mid-low rectal cancer patients exhibiting a clinical complete or near-complete response to neoadjuvant chemoradiotherapy: Transanal endoscopic microsurgery --A multicenter prospective case-control clinical tria…
Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Systematic Review and Meta-analysis.Eyck BM, Onstenk BD, Noordman BJ, et al. Ann Surg. 2020 Feb;271(2):245-256. DOI: 10.1097/SLA.0000000000…
Detecting residual disease after neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: The prospective multicentre preSINO trial.Yang Y, Liu Z, Wong I, et al. Br J Surg. 2025 Feb 1;112(2):znaf004. DOI: 10.1093/bjs/znaf004.…
Neoadjuvant chemoradiotherapy plus sequential tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): A single-arm, bicentric, phase 2 trial.Yang J, Liu C, Zuo Z, et al. Radiother Oncol. 2025 May;206:110797. DOI: 10.1016/…
Long-Term Survival Analysis of Neoadjuvant Chemoradiotherapy Versus Adjuvant Chemoradiotherapy for Locally Advanced Low Rectal Cancer.Chen S, Wu R, Wan J, et al. Cancer Med. 2025 Aug;14(15):e71042. DOI: 10.1002/cam4.71042. PMID: 40709606. …
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. Rahma OE, Yothers G, Hong TS, et al. JAMA Oncol. 2021 Aug 1;7(8):1225-1230. DOI: 10.100…
Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancerTsukada Y, Bando H, Inamori K, et al. Br J Cancer. 2024 Jul;131(2):283-289. DOI…
Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial. van der Wilk BJ, Eyck BM, Wijnhove…
A single-arm confirmatory trial of S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumors.Takamochi K, Suzuki K, Okada M, et al. Lung Cancer. 2025 Apr;202:108506. DOI: 10.1016/j.lungcan.…
Chemoradiotherapy and Local Excision vs Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer: The TAUTEM Randomized Clinical Trial.Serra-Aracil X, Pericay C, Cidoncha A, et al. JAMA Surg. 2025 Jul 1;160(7):783-793. DOI: 10.1001/jamas…
Differential effects of RAS mutations on chemoradiotherapy and total neoadjuvant therapy in locally advanced rectal cancer. Haraguchi E, Akiyoshi T, Noguchi T, et al. Int J Cancer. 2025 Jul 14. DOI: 10.1002/ijc.70040 Epub ahead of print. P…
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.Conroy T, Bosset JF, Etienne PL, et a…
Neoadjuvant chemotherapy versus long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis of 5,168 cases.Zhou W, Wang X, Dan J, et al. Front Oncol. 2025 Jun 26;15:1542885. DOI: 10.3…
currence Patterns of Esophageal Adenocarcinoma in the Phase III ESOPEC Trial Comparing Perioperative Chemotherapy With Preoperative Chemoradiotherapy.Hoeppner J, Schmoor C, Brunner T, et al. J Clin Oncol. 2025 Jul 9:JCO2500948.DOI: 10.1200…
